BioLine Rx (XTAE:BLRX) EV-to-Revenue : 5.07 (As of May. 01, 2024)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BioLine Rx's enterprise value is ₪90.97 Mil. BioLine Rx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪17.95 Mil. Therefore, BioLine Rx's EV-to-Revenue for today is 5.07.

The historical rank and industry rank for BioLine Rx's EV-to-Revenue or its related term are showing as below:

XTAE:BLRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.46 Med: 11.13 Max: 16.23
Current: 5.03

During the past 13 years, the highest EV-to-Revenue of BioLine Rx was 16.23. The lowest was 3.46. And the median was 11.13.

XTAE:BLRX's EV-to-Revenue is ranked better than
60.72% of 1031 companies
in the Biotechnology industry
Industry Median: 7.91 vs XTAE:BLRX: 5.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), BioLine Rx's stock price is ₪0.176. BioLine Rx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.02. Therefore, BioLine Rx's PS Ratio for today is 10.35.

BioLine Rx EV-to-Revenue Historical Data

The historical data trend for BioLine Rx's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx EV-to-Revenue Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

16.52

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	16.52

Competitive Comparison of BioLine Rx's EV-to-Revenue

For the Biotechnology subindustry, BioLine Rx's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioLine Rx's EV-to-Revenue falls into.

BioLine Rx EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BioLine Rx's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	90.971	/	17.95
	=	5.07

BioLine Rx's current Enterprise Value is ₪90.97 Mil.
BioLine Rx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪17.95 Mil.

BioLine Rx (XTAE:BLRX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BioLine Rx's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.176	/	0.017
	=	10.35

BioLine Rx's share price for today is ₪0.176.
BioLine Rx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.02.

BioLine Rx EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioLine Rx's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.